Louie Pasculli

Interim phase 2 data from the FORWARD-53 study suggest the exon-skipping therapy WVE-N531 was well tolerated and produced sustained dystrophin expression, reduced fibrosis, and functional improvements in boys with DMD amenable to exon 53 skipping.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Seronegative generalized myasthenia gravis!

A recently published position statement from the American Headache Society recommends annual screening for migraine in girls and women, highlighting the potential role of tools like the ID Migraine screener to improve identification.

Large-scale proteomic and transcriptomic analyses position the synaptic protein NRN1 as a resilience-linked therapeutic candidate in Alzheimer disease, though validation remains preclinical.

A Large cohort analysis of more than 159,000 adults found greater adherence to multiple healthy dietary patterns—particularly the DASH diet—was linked to a significantly lower risk of subjective cognitive decline in midlife.

A cross-sectional analysis of nearly 28,000 middle-aged adults found that excessive daytime sleepiness is strongly associated with both sleep characteristics and modifiable psychological factors, highlighting the need for integrated prevention strategies.

R. Scott Turner, PhD, MD, director of the memory disorders program at MedStar Georgetown University Hospital, discussed the importance of investigating environmental risk factors in Alzheimer disease.

Neurologists Esther Bui, MD, and Angela O'Neal, MD, talked about the INSIGHT network, a collaborative global initiative designed to advance medical education in women’s neurology.

A clinician and researcher at the University of California, San Francisco highlighted how agentic AI frameworks are being integrated into real-world multiple sclerosis research to streamline big data analysis and accelerate clinically meaningful discovery. [Watch Time: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is diagnostic workup for multiple system atrophy!

Andrei Alexandrov, MD, an award-winning leader in stroke research and clinical care, discussed the clinical impact of the latest stroke guidelines and their implications for diagnosis and care.

In early-morning shift workers with shift work disorder, solriamfetol significantly improved objective and subjective measures of sleepiness compared with placebo in a trial published in the New England Journal of Medicine.

Kyle Marden, MD, sports neurologist at Northwestern Medicine, discussed the growing role of sports neurologists and new data supporting the feasibility of quantitative pupillometry as part of a multimodal approach to concussion diagnosis and recovery tracking.

Off-label rimegepant was associated with patient-reported acute migraine improvement and no new safety signals in a small retrospective review of adolescent patients.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Dravet syndrome treatment paradigm!

Experts shared their clinical perspectives on trending topics at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held February 5-7, 2026.

An associate professor in neurosurgery at Duke University discussed his presentation on novel meningeal immune interactions and interferon signaling in multiple sclerosis at the ACTRIMS Forum 2026. [WATCH TIME: 3 minutes]

The FDA granted premarket approval to Balt Inc.’s Squid liquid embolic agent for middle meningeal artery embolization, offering a minimally invasive option to reduce treatment failure in patients with large symptomatic chronic subdural hematomas.

A pediatric neurologist at the UCL Institute of Neurology in London, England discussed how pediatric-onset MS is marked by intense inflammation, unique neurodevelopmental considerations, and evolving treatment paradigms at ACTRIMS 2026. [WATCH TIME: 5 minutes]

A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FDA-Approved Drugs for Duchenne Muscular Dystrophy!

An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard dual antiplatelet therapy.

The Allen Geller distinguished professor of immunology at Duke University School of Medicine discusses the connection between Epstein Barr Virus and Multiple Sclerosis, citing decades of research that position EBV as a leading environmental risk factor and a potential therapeutic target in MS. [WATCH TIME: 4 minutes]

Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, demonstrated efficacy in children and adolescents with episodic migraine in full data release.

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.